The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 16, 2019

Filed:

Feb. 18, 2015
Applicant:

Baylor Research Institute, Dallas, TX (US);

Inventors:

Ajay Goel, Dallas, TX (US);

Lucia Perez-Carbonell, Dallas, TX (US);

C. Richard Boland, Dallas, TX (US);

Assignee:

Baylor Research Institute, Dallas, TX (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12Q 1/68 (2018.01); A61K 31/513 (2006.01); C12N 15/113 (2010.01); G06F 19/00 (2018.01); C12Q 1/6886 (2018.01); G16H 40/63 (2018.01); G16H 10/60 (2018.01);
U.S. Cl.
CPC ...
C12Q 1/6886 (2013.01); A61K 31/513 (2013.01); C12N 15/113 (2013.01); G06F 19/00 (2013.01); G16H 10/60 (2018.01); G16H 40/63 (2018.01); C12N 2310/14 (2013.01); C12N 2320/30 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/158 (2013.01); C12Q 2600/178 (2013.01); Y02A 90/22 (2018.01); Y02A 90/26 (2018.01);
Abstract

Embodiments provide methods and compositions related to determining treatments for colorectal cancer patients by detection and analysis of the expression level of miRNA such as miR-320e in the patients. Embodiments provide predictive, prognostic and/or diagnostics methods by identifying miRNAs that are useful for clinical management of cancer patients, particularly colorectal cancer patients or patients at risk or determined to have colorectal cancer. Methods and compositions are based, in part, on the discovery that expression of certain miRNAs in cancer patients is associated with advancing cancer stages and/or can predict the responsiveness of cancer therapy, and can, therefore, provide basis for designing treatment strategies. In particular embodiments, the miRNA molecule is miR-320, particularly miR-320e.


Find Patent Forward Citations

Loading…